PepDialed

Reference · cited facts

Tesamorelin

Egrifta / Egrifta SV / GHRH analogHalf-life ≈26–38 minutes (short)FDA-approvedReviewed July 2026

Educational information and a math tool only — not medical advice, a dose recommendation, or an endorsement of peptide use. Consult a licensed healthcare provider before starting, stopping, or changing anything.

Class / mechanism
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH); it signals the pituitary to release the body's own growth hormone rather than supplying growth hormone directly.
SOURCE [1]
Regulatory status
FDA-approved (initial U.S. approval 2010) for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy — that is its only FDA-approved indication. Prescription only. Supplied as a lyophilized powder that is reconstituted before subcutaneous injection. As of 2026-07-16 and subject to change.
FDA · July 2026
Reported half-life
≈26–38 minutes (short)
PUBMED
Human evidence
Established (FDA-approved)
LITERATURE

What the literature reports

  • Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH); it signals the pituitary to release the body's own growth hormone rather than supplying growth hormone directly.
  • It is FDA-approved (2010) for one indication — reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The brand names Egrifta, Egrifta SV and Egrifta WR are used for identification only.
  • The FDA-approved product is supplied as a lyophilized (freeze-dried) powder that is reconstituted with a sterile diluent before injection, so the reconstitution math applies to the approved product itself.
  • Its blood half-life is short — reported as roughly 26–38 minutes — consistent with the rapid absorption the FDA prescribing information describes.

Honest caveats

  • This is a prescription medicine — obtain and use it only through a licensed clinician.
  • It is FDA-approved for a single indication (HIV-associated lipodystrophy); this page states that indication as a neutral fact and makes no recommendation for any use.
  • Reference facts only — no dose, protocol, or benefit is stated or implied.

Reconstitution calculator

Enter your own vial size, BAC water and target dose — get exact syringe units.

Open Tesamorelin calculator

Sources

  1. [1] FDA — Egrifta SV prescribing information (NDA 022505)
  2. [2] DailyMed — Egrifta SV (tesamorelin) label